Dendreon Corp. (DNDN-NASDAQ) was downgraded from an “Outperform” rating to a “Market Perform” rating. The brokerage sees uncertainties and risks going into an expected meeting FDA meeting over the recent “approvable and request for more data” on its Provenge for the treatment of late-stage prostate cancer. It was back around April 11 that JMP downgraded the shares to an Outperform rating. Shares are trading down about 3% at $6.62 in pre-market trading.
Jon C. Ogg
May 24, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
ALERT: Take This Retirement Quiz Now (Sponsored)
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
